Heimdall supplies software and sensors for monitoring overhead power lines. Photo via heimdallpower.com

A Norway-based provider of technology for power grids whose U.S. headquarters is in Houston has raised a $25 million series B round of funding.

The venture capital arm of Polish energy giant Orlen, Norwegian cleantech fund NRP Zero, and the Norway-based Steinsvik Family Office co-led Heimdall Energy's round. Existing investors, including Investinor, Ebony, Hafslund, Lyse, and Sarsia Seed, chipped in $8.5 million of the $25 million round.

“This funding gives us fuel to grow internationally, as we continue to build our organization with the best people and industry experts in the world,” Jørgen Festervoll, CEO of Heimdall, says in a news release.

Founded in 2016, Heimdall supplies software and sensors for monitoring overhead power lines. The company says its technology can generate up to 40 percent in additional transmission capacity from existing power lines.

Heimdall entered the U.S. market in 2023 with the opening of its Houston office after operating for several years in the European market.

“Heimdall Power has built itself a unique position as an enabler for the ongoing energy transition, with fast-increasing electricity demand and queues of renewables waiting to get connected,” says Marek Garniewski, president of Orlen’s VC fund.

Heimdall says it will put the fresh funding toward scaling up production and installation of its “magic ball” sphere-shaped sensors. In the U.S., these sensors help operators of power grids maximize the capacity of the aging power infrastructure.

“In the United States alone, there are over 500,000 miles of power lines — most of which have a far higher transmission capacity than grid operators have historically been able to realize. To increase capacity, many have launched large-scale and expensive infrastructure projects,” Heimdall says.

Now, the U.S. government has stepped in to ensure that utilities are gaining more capacity from the existing infrastructure, aiming to upgrade 100,000 miles of transmission lines over the next five years.

Heimdall's technology enables grid operators and utilities to boost transmission capacity without undertaking lengthy, costly infrastructure projects. Earlier this year, the company kicked off the largest grid optimization project in the U.S. with Minnesota-based Great River Energy.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.